Blueprint Medicines (NASDAQ: BPMC) and SAGE Therapeutics (NASDAQ:SAGE) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.
Institutional and Insider Ownership
83.5% of Blueprint Medicines shares are owned by institutional investors. Comparatively, 95.3% of SAGE Therapeutics shares are owned by institutional investors. 3.4% of Blueprint Medicines shares are owned by company insiders. Comparatively, 6.1% of SAGE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Blueprint Medicines has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, SAGE Therapeutics has a beta of 3.06, suggesting that its stock price is 206% more volatile than the S&P 500.
This table compares Blueprint Medicines and SAGE Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Blueprint Medicines and SAGE Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Blueprint Medicines||$27.77 million||122.36||-$72.49 million||($3.41)||-23.24|
|SAGE Therapeutics||N/A||N/A||-$158.98 million||($6.87)||-25.60|
Blueprint Medicines has higher revenue and earnings than SAGE Therapeutics. SAGE Therapeutics is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings for Blueprint Medicines and SAGE Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Blueprint Medicines currently has a consensus price target of $83.78, indicating a potential upside of 5.73%. SAGE Therapeutics has a consensus price target of $171.21, indicating a potential downside of 2.64%. Given Blueprint Medicines’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Blueprint Medicines is more favorable than SAGE Therapeutics.
Blueprint Medicines beats SAGE Therapeutics on 8 of the 13 factors compared between the two stocks.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
SAGE Therapeutics Company Profile
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.